CGEM MT Newswires 19 hours ago Wedbush Raises Price Target on Cullinan Therapeutics to $34 From $25, Keeps Outperform Rating
CGEM MT Newswires 2 days ago Cullinan Therapeutics Says Data From Early-Stage Acute Myeloid Leukemia Trial Showed Multiple Complete Responses
CGEM GlobeNewswire 2 days ago Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
